Since C1-Ten is upregulated under insulin-resistant and diabetic conditions (i.e., dexamethasone and rodent diabetic models), a chemical inhibitor for C1-Ten PTPase activity might provide a potential therapeutic approach against insulin resistance and type 2 diabetes. The gene discussed is TNS2; the disease is type 2 diabetes mellitus.